Tanshinlactone triggers methuosis in breast cancer cells via NRF2 activation

Wanjun Lin, Zifeng Huang, Xuening Zhang, Dayuan Zheng, Yanchao Yang, Meina Shi, Dongfang Yang, Tien‐Min Gabriel Chu, Wenzhe MaFrontiers in Pharmacology 2025 · DOI

Abstract

Tanshinlactone (TSL), a novel therapeutic agent, is capable of selectively inhibiting ER+ and HER2+/EGFR+ breast tumors through a unique mechanism of inducing catastrophic macropinocytosis. This regimen holds promise for targeted therapy with minimized side effects and offers a new therapeutic avenue for breast cancer patients with drug-resistant diseases.

Introduction

Breast cancer remains a leading cause of mortality among women, largely due to the development of multi-drug resistance (MDR) and the severe side effects associated with current therapies. Most existing treatments aim to trigger apoptosis (programmed cell death). However, cancer cells frequently evolve to evade apoptosis, rendering them resistant to standard chemotherapy.

Researchers have recently identified Tanshinlactone (TSL), a compound derived from the traditional Chinese herb Salvia miltiorrhiza, as a potential solution. TSL selectively kills specific breast cancer cells by inducing a rare form of non-apoptotic cell death called methuosis. By over-activating the NRF2 pathway, TSL causes cancer cells to undergo uncontrolled vacuolization, effectively causing them to "drink" themselves to death.

Mechanism: NRF2 and the "Traffic Jam"

While NRF2 is typically known as a master regulator of antioxidant responses that protects cells from stress, this study highlights a paradoxical role: its over-activation can drive a gene signature (including EGF, CDC42, and SDC1) that triggers lethal macropinocytosis.

TSL induces a cellular "traffic jam." It doesn't just increase fluid uptake; it causes the resulting macropinosomes to fail in their fusion with lysosomes for degradation or their recycling back to the plasma membrane. This leads to a massive accumulation of fluid-filled vacuoles that displace the cytoplasm and eventually cause the cell to rupture. Because this mechanism is non-apoptotic, TSL remains effective against cells that have developed resistance to common treatments like lapatinib.

Experimental Validation

The study employed a multi-disciplinary approach to validate TSL’s mechanism, using a broad panel of cell lines:

  • Sensitive Lines: SK-BR-3, MDA-MB-453, BT-474, ZR-75-1, MCF7, T-47D, and MDA-MB-468.
  • Resistant Lines: Triple-negative breast cancer (TNBC) lines like MDA-MB-231 and BT-549, and normal control lines like MCF10A.

In addition to standard cell viability and colony formation assays, the team used high-resolution imaging and fluorescent tracing (FITC-dextran) to quantify fluid-phase uptake. A murine xenograft tumor explant assay (histoculture) was also utilized to preserve 3D tumor architecture while testing drug exposure.

Key Results and Selectivity

TSL demonstrated high potency against sensitive breast cancer lines, with IC50 values ranging from 1.07 to 6.92 µM. In contrast, TNBC and normal cells remained largely unaffected, with IC50 values exceeding 20 µM.

Dose-response curves showing the inhibitory effect of TSL on cell viability across various breast cancer cell lines.

Colony formation assays further confirmed this selectivity. While sensitive lines showed a dramatic reduction in colony numbers at low micromolar concentrations, resistant TNBC lines (MDA-MB-231 and BT549) showed minimal response even at higher doses.

Colony formation assay results highlighting the selective sensitivity of ER+ and HER2+ lines compared to TNBC lines.

Molecular analysis confirmed that TSL significantly upregulated NRF2 and its downstream targets. Blocking NRF2 with the inhibitor ML385 almost entirely rescued cells from TSL-induced death, proving the pathway's necessity in the methuotic process.

Conclusion and Future Directions

TSL offers a promising strategy to bypass traditional drug resistance by targeting a non-apoptotic pathway. However, several challenges remain before clinical transition. TSL is currently difficult to obtain in large quantities via plant extraction, and an efficient synthetic route has yet to be established. Furthermore, while the link to NRF2 is clear, the primary molecular target that TSL initially binds to remains unknown. Future work will focus on chemical proteomics to identify this target and long-term animal studies to evaluate systemic safety and pharmacokinetics.

Summary updated

Abstract

Tanshinlactone as a novel therapeutic agent, is capable of selectively inhibiting ER+ and HER2+/EGFR + breast tumors through a unique mechanism of inducing catastrophic macropinocytosis. This regimen holds promise for targeted therapy with minimized side effects and offers a new therapeutic avenue for breast patients with drug-resistant diseases.
BibTeX
@inproceedings{lin2025tanshinlactone,
  author = {Wanjun Lin and Zifeng Huang and Xuening Zhang and Dayuan Zheng and Yanchao Yang and Meina Shi and Dongfang Yang and Tien‐Min Gabriel Chu and Wenzhe Ma},
  title = {{Tanshinlactone triggers methuosis in breast cancer cells via NRF2 activation}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2024.1534217},
}
Figure